0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Glatiramer Acetate–Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma FREE

Monica M. Madray, MD; John F. Greene Jr, MD; David F. Butler, MD
[+] Author Affiliations

Author Affiliations: Departments of Dermatology (Drs Madray and Butler) and Pathology (Dr Greene), Scott and White Memorial Hospital and Clinic, Temple, Texas.


Arch Neurol. 2008;65(10):1378-1379. doi:10.1001/archneur.65.10.1378.
Text Size: A A A
Published online

ABSTRACT

Objective  To report the association of the development of a primary, cutaneous, anaplastic large-cell lymphoma after initiation of glatiramer acetate treatment of a patient with relapsing-remitting multiple sclerosis.

Design  Case report.

Setting  Dermatology outpatient clinic.

Patient  A 33-year-old white woman developed an erythematous nodule on her leg 4 months after starting treatment with glatiramer acetate. Biopsy showed primary, cutaneous, anaplastic large-cell lymphoma. Further evaluation showed no systemic involvement.

Intervention  Radiation therapy induced a complete remission.

Conclusions  Several T-cell–mediated skin conditions have been associated with the use of glatiramer acetate, such as pseudolymphoma, drug eruptions, and erythema nodosum. We report the association of a T-cell malignancy with the use of glatiramer acetate.

Figures in this Article

Glatiramer acetate (GA) (Copaxone; Teva Pharmaceutical Industries Ltd, Kansas City, Missouri), an injectable polypeptide immunomodulatory agent, is currently approved for the treatment of relapsing-remitting multiple sclerosis. Although the exact mechanism of action remains unknown, GA appears to alter immune function by acting on CD8+ T cells, antigen-presenting cells, monocytes, and B cells and by altering T-cell differentiation.1 Reported cutaneous adverse events have included erythema at the injection site, local necrosis, and erythema nodosum.2,3 One patient was reported to develop a T-cell figurate erythemalike pseudolymphoma that resolved with continued treatment.4 We describe the clinicopathologic features of a CD30+, primary, cutaneous, anaplastic large-cell lymphoma developing after initiation of GA therapy.

REPORT OF A CASE

A 33-year-old white woman began treatment with GA, 20 mg subcutaneously every day, 9 months after being diagnosed with multiple sclerosis. Four months after starting treatment, she developed an 8-mm, firm, nontender, erythematous papule at the left pretibial region. After slowly enlarging for 6 months it was surgically excised, with visible tumor extending to the fascia. The patient was otherwise healthy and without lymphadenopathy. Other medications included paroxetine hydrochloride and desogen, which are not known to cause lymphomas or pseudolymphomas. Family history was negative for lymphoproliferative disorders. Hematology-oncology consultation was obtained. Laboratory evaluation showed a normal complete blood cell count, serum chemistry results, lactate dehydrogenase level, and β2-microglobulin level. Results of computed tomography of the chest, abdomen, and pelvis were normal. Bone marrow biopsy and more extensive imaging were deferred, as was molecular analysis.

Hematoxylin-eosin–stained sections showed a diffuse, bottom-heavy, dermal, nodular infiltrate of atypical lymphoid cells extending into the subcutaneous tissue in sheets (Figure 1). The infiltrate was positive for CD3 and more than 75% positive for CD30 (Figure 2). Staining for anaplastic lymphoma kinase, epithelial membrane antigen, keratin, Ber-EP4, and CD15 was negative. Mitotic figures were frequent.

Place holder to copy figure label and caption
Figure 1.

Diffuse infiltrate of large pleomorphic lymphoid cells (hematoxylin-eosin, original magnification ×400).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Staining with CD30 immunoperoxidase shows positive results for most of the anaplastic cells (original magnification ×100).

Graphic Jump Location

The clinical findings of a persistent, enlarging, solitary skin nodule along with the histologic features of an anaplastic CD30+ infiltrate present in sheets favor a diagnosis of primary, cutaneous, anaplastic large-cell lymphoma rather than lymphomatoid papulosis or pseudolymphoma.5

On subsequent examination, mild surrounding induration and smaller papules were noted in the edges of the surgical scar. Radiation therapy was administered and the residual lesion was completely resolved. Because of the limited nature of the lymphoma, good prognosis, and remarkable improvement of the patient's multiple sclerosis symptoms, GA treatment was continued.

COMMENT

Drug-associated, nodular, cutaneous T-cell pseudolymphomas are rare but have been reported with the use of anticonvulsants. Carbamazepine was reported to induce a CD30+, primary, anaplastic large-cell lymphoma.6 Differentiation of pseudolymphoma from lymphoma may be difficult and relies on the histologic pattern, cellular morphology, clonality, immunohistochemical markers, and clinical course. The development of our patient's primary, cutaneous, anaplastic large-cell lymphoma at a site distant from the injection would suggest a systemic effect by stimulation and/or selection of an aberrant clone of T cells.

Glatiramer acetate is a normally safe, well-tolerated, effective medication used in the treatment of multiple sclerosis. It is believed to alter immune function by causing a shift from reactive type 1 helper T cells to reactive type 2 helper T cells and ultimately dampening inflammation within the central nervous system.1 The temporal association of starting treatment with GA and the T-cell modulating properties of this drug implies a possible relationship with the development of the primary, cutaneous, anaplastic large-cell lymphoma in our patient. Clinicians should be aware of this potential association to better inform patients of the risks of using the drug.

ARTICLE INFORMATION

Correspondence: David F. Butler, MD, Department of Dermatology, Scott and White Memorial Hospital, 2401 S 31st St, Temple, TX 76508 (dfbutler@swmail.sw.org).

Accepted for Publication: June 2, 2008.

Author Contributions: All of the authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Madray and Butler. Acquisition of data: Madray and Greene. Analysis and interpretation of data: Madray, Greene, and Butler. Drafting of the manuscript: Madray. Critical revision of the manuscript for important intellectual content: Madray, Greene, and Butler. Administrative, technical, and material support: Greene and Butler. Study supervision: Greene.

Financial Disclosure: None reported.

REFERENCES

Weber  MSHohlfeld  RZamvil  SS Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007;4 (4) 647- 653
PubMed Link to Article
Bosca  IBosca  MBelenguer  A  et al.  Necrotising cutaneous lesions as a side effect of glatiramer acetate. J Neurol 2006;253 (10) 1370- 1371
PubMed Link to Article
Thouvenot  EHillaire-Buys  DBos-Thompson  MA  et al.  Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Mult Scler 2007;13 (7) 941- 944
PubMed Link to Article
Nolden  SCasper  CKuhn  APetereit  HF Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. Mult Scler 2005;11 (2) 245- 248
PubMed Link to Article
Droc  CCualing  HDKadin  ME Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. Cancer Control 2007;14 (2) 124- 132
PubMed
Di Lernia  VViglio  ACattania  MEmilia  RPaulli  M Carbamazepine-induced, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Dermatol 2001;137 (5) 675- 678
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Diffuse infiltrate of large pleomorphic lymphoid cells (hematoxylin-eosin, original magnification ×400).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Staining with CD30 immunoperoxidase shows positive results for most of the anaplastic cells (original magnification ×100).

Graphic Jump Location

Tables

References

Weber  MSHohlfeld  RZamvil  SS Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007;4 (4) 647- 653
PubMed Link to Article
Bosca  IBosca  MBelenguer  A  et al.  Necrotising cutaneous lesions as a side effect of glatiramer acetate. J Neurol 2006;253 (10) 1370- 1371
PubMed Link to Article
Thouvenot  EHillaire-Buys  DBos-Thompson  MA  et al.  Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Mult Scler 2007;13 (7) 941- 944
PubMed Link to Article
Nolden  SCasper  CKuhn  APetereit  HF Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. Mult Scler 2005;11 (2) 245- 248
PubMed Link to Article
Droc  CCualing  HDKadin  ME Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. Cancer Control 2007;14 (2) 124- 132
PubMed
Di Lernia  VViglio  ACattania  MEmilia  RPaulli  M Carbamazepine-induced, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Dermatol 2001;137 (5) 675- 678
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

862 Views
8 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs